[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Southampton\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":358},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,62,90,111,138,170,194,218,246,279,309,330],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054036","nutritional-supplementation-on-physiological-and-metabolic-markers-in-females-100054036",false,"NCT07615777","Nutritional Supplementation on Physiological and Metabolic Markers in Females","A Pilot Study Investigating the Effects of a Nutritional Supplement on Physiological and Metabolic Markers in 38-55-year-old Females","Inclusion Criteria:\n\n* Assigned sex at birth is female\n* Aged 38-55 years\n* Experiencing irregular menstrual cycles but not amenorrheic for more than 12 months or have at least one of the following recent symptoms (i.e., from 38 years onwards): (1) hot flushes, (2) sleep disturbances, (3) mood swings, (4) concentration difficulties, (5) bloating or (6) weight gain.\n\n  * Willing to avoid taking other food supplements during the study period\n  * Able to provide written informed consent\n\nExclusion Criteria:\n\n* Diabetes\n* BMI \\\u003C18.5 kg\u002Fm2\n* Pregnant or trying to get pregnant\n* No active cancer or cancer within last 5 years\n* Total Hysterectomy\n* Known allergies to cinnamon extract, chromium, berberine, myo-inositol\n* Currently taking part in research, or have done within the last 3 months\n* Diagnosed autoimmune diseases\n* Diagnosed hypoglycemia",true,"FEMALE","38 Years","55 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if a 12-week nutritional supplement can result in significant changes in the body composition of 38-55-year-old females. The main questions it aims to answer are:\n\n* Does a 12-week nutritional supplementation with myo-inositol, berberine, cinnamon, and chromium lead to significant changes in body composition (e.g. body mass index, body fat composition) in females aged 38-55 compared to placebo?\n* Does a 12-week nutritional supplementation with myo-inositol, berberine, cinnamon, and chromium lead to significant changes in small molecules (metabolites) in plasma and urine, menopause-related symptoms, and physical performance (e.g. grip strength) in females aged 38-55 compared to placebo? Researchers will compare the nutritional supplement to a placebo (a look-alike substance that contains no nutritional supplement) to see if the intervention works to change body composition in females aged 38-55.\n\nParticipants will:\n\n* Sign a consent form before any procedures begin\n* Attend two visits to the clinical research facility at Southampton General Hospital over 12 weeks.\n* Fast before visit's and provide blood and urine samples at each visit\n* Undergo measurements at each visit, including waist and hip circumferences, grip and leg strength, and body composition.\n* Complete questionnaires about general health, menopause-related changes, alcohol consumption, physical activity, and diet.\n* Take 1 capsule 3 times a day at the onset of a meal (once in the morning, once at midday, and once in the evening) for the first 10 days.\n* Take 3 capsules 3 times a day at the onset of a meal (once in the morning, once at midday, and once in the evening) from day 11 to day 84.\n* Record supplement intake in a daily compliance diary during the study",[28,29],"Perimenopausal Women","Body Composition Changes",[31,32,33,34],"Perimenopause","menopause","metabolism","metabolomics","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-07-09",{"date":43,"type":22},"2026-12",{"name":45,"class":46},"University of Southampton","OTHER",1,{"id":49,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":26,"conditions":52,"keywords":53,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":47},"100640067",{"count":21,"type":22},[25],[28,29],[31,32,33,34],"NOT_YET_RECRUITING","2026-05-29",{"date":57,"type":39},"2026-06-03",{"date":59,"type":22},"2026-06-01",{"date":43,"type":22},{"name":45,"class":46},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":47},"100638919","phase-2-selectmeso-a-trial-for-patients-with-relapsed-malignant-mesothelioma-selectmeso1-a-trial-of-bms-986504-in-patients-with-mtap-deficient-relapsed-mesothelioma-100638919","NCT07602946","SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma","SynthEtic LEthal Cancer Therapy in Mesothelioma (SELECTmeso): a Molecularly Stratified Multi-arm Phase II Platform Trial for Patients With Relapsed Malignant Mesothelioma Candidate Specific Trial: SELECTmeso1 A Phase II Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma","SELECTmeso","SELECTmeso Platform Inclusion Criteria:\n\n1. Histological confirmation of malignant mesothelioma (pleural, or non-pleural)\n2. Evidence of disease progression on CT scan\n3. Available archival tissue block for molecular screening or existing molecular screening result via validated NHS diagnostic grade immunohistochemistry-based assays\n4. Previous treatment with at least 1st line licensed systemic anti-cancer therapy. Patients can have received more than one prior line of systemic therapy\n5. No progressing central nervous system disease and not receiving any concurrent systemic therapy at the time of screening\n6. ECOG performance status 0-1\\*\n7. 16 years of age and older\n8. Expected survival of ≥12 weeks\n9. Consent to provide baseline tumour tissue sample for trial\n10. Patients must have signed and dated a REC-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal patient care\n\nSELECTmeso1 Inclusion Criteria:\n\nA. Evidence of MTAP deficient. MTAP deficiency detected by a validated immunohistochemistry test conducted under the SELECTmeso master protocol, in the Leicester NHS pathology department B. Willing to consent and able to undergo required procedures to provide blood C. 18 years of age and older\n\nD. Adequate organ function, including the following:\n\n1. Adequate bone marrow reserve:\n\n   i. Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL, ii. WBC ≥ 3 x 109\u002FL, iii. Haemoglobin ≥ 85g\u002FL, iv. Platelet count ≥100 × 109\u002FL\n2. Adequate liver function and renal:\n\n   i. Bilirubin \\\u003C 1.5 x ULN ii. AST \\& ALT \\\u003C3 x ULN iii. Creatinine clearance \\> 45ml\u002Fmin.\n3. INR ≤ 1.5 × institutional ULN unless on a stable dose of an anticoagulant with no unexplained elevation of INR E. Participants must provide informed consent to SELECTmeso1 before any study specific procedures. The PI must confirm the eligibility of a participant in the participant's medical notes before enrolment F. Women of childbearing potential (WOCBP) participants agree to use contraception (see Section 5.3) while participating in this study, and for a period of 6 months after the last dose of study treatment G. Men whose partner is a WOCBP agree to use contraception (see Section 5.3) while participating in this study, and for a period of 6 months after the last dose of study treatment\n\nSELECTmeso Platform Exclusion Criteria:\n\n1. Patients with a diagnosis of a second malignancy (except prostate or cervical cancer in remission, patients with a diagnosis of basal cell carcinoma or non-muscle invasive bladder cancer, who can all be included)\n2. New York Heart Association Class II or greater congestive heart failure\n3. Patients requiring long term oxygen therapy\n4. Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial\n5. Patients on active treatment in another clinical trial\n\nSELECTmeso1 Exclusion Criteria:\n\nH. Diagnosis, detection, or treatment of another type of cancer 5 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin, non-muscle invasive bladder cancer that has been definitively treated), or prostate or cervical cancer in remission I. Have received treatment with an agent that has no marketing authorisation, within 14 days of study entry. If the Participants has participated in a different SELECTmeso CST, they must comply with the washout period for that CST J. Participants who are pregnant or breast feeding K. Uncontrolled CNS disease. Asymptomatic brain metastases are allowed if previously treated with radiotherapy \\> 28 days prior to starting BMS-986504 L. Palliative radiotherapy within the mRECIST 1.1 area in the 4 weeks prior to baseline CT scan M. Participants with severe hepatic insufficiency or severe renal impairment N. Uncontrolled\u002Fsymptomatic or significant cardiovascular conditions within 6 months prior to enrolment, including, but not limited to, any of the following: i) Cardiac angioplasty or stenting, unstable angina pectoris, myocardial infarction, stroke\u002Ftransient ischemic attack, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, New York Heart Association (NYHA) class III-IV congestive heart failure, pericarditis, atrial fibrillation or other arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsades de pointes).Ongoing need for a medication with a known risk of Torsades de Pointes that cannot be switched to alternative treatment prior to study entry\n\nO. Participant has any of the following cardiac criteria:\n\ni. Mean resting corrected QT interval (QTcF) \\>470 msec ii. Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block iii. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval (including IV ondansetron) iv. Ejection fraction (EF) \\\u003C50% or the lower limit of normal of the institutional standard. A historic measurement of EF no older than 6 months prior to first administration of trial drug can be accepted provided that there is clinical evidence that the Participant's cardiac disease has not significantly worsened since this measurement in the opinion of the Investigator or of the treating physician or both P. Active bleeding, significant risk of haemorrhage (e.g. previous severe gastrointestinal bleeding, previous haemorrhagic stroke at any time), or current bleeding disorder (e.g. haemophilia, von Willebrand disease) Q. Recovery from the adverse effects of prior therapy at the time of enrolment to baseline or ≤ Grade 1 (excluding alopecia, peripheral neuropathy, and parameters superseded by other eligibility criteria \\[eg, haematology parameters\\]). Note: Participants with prior endocrine adverse effects are permitted to enrol if they are stably maintained on appropriate replacement therapy and are asymptomatic. Major surgery, open biopsy or significant traumatic injury within 28 days before the start of study treatment or planned within 6 months after screening R. Participants who have received live\u002Fattenuated vaccine within 30 days of first treatment. The use of inactivated seasonal influenza vaccines will be permitted on study without restriction S. Pre-existing duodenal stent and\u002For history of gastrointestinal disease or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications T. Previous significant surgical resection of stomach or small bowel U. Participants who have difficulty swallowing V. Participants who have received prior treatment with a PRMT5 inhibitor including BMS-986504, or MAT2A inhibitor W. Participants with active bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment) fungal infection or detectable viral infection or viral load (such as known human immunodeficiency virus positivity) X. Active viral hepatitis, including the following: i) Any positive test result for hepatitis B virus (HBV) indicating presence of virus, eg, HBV DNA positive would be excluded. Participants with anti-HBsAg positive in line with prior vaccination are eligible to enrol. ii) Any positive test result for hepatitis C virus (HCV) indicating presence of active viral replication (detectable HCV-RNA). iii) Participants with positive HCV antibody and an undetectable HCV RNA are eligible to enrol. Screening is not required for enrolment Y. Known HIV positive with an AIDS-defining opportunistic infection within the last year, or a current CD4 count \\\u003C 350 cells\u002FμL. Participants with HIV are eligible if they have received established ART for at least 4 weeks prior to randomization and continue on ART as clinically indicated while enrolled on study. Viral serology only to be conducted if locally mandated and, if done, must be performed within 28 days prior to randomization. Screening is not required for enrolment Z. Known severe hypersensitivity to study treatment and\u002For any of its excipients AA. Ongoing need for a medication known as a strong inhibitor or strong inducer of CYP3A4 and\u002For P-glycoprotein or a proton-pump inhibitor that cannot be switched to an alternative treatment prior to enrolment. The following drug interaction databases and other literature can be utilized to determine the CYP3A4\u002FP-gp inhibitors and inducers. Examples of CYP3A4\u002FP-gp inhibitors and inducers are also provided in See Section 7.8 for further information BB. Prior organ allograft CC. Any botanical preparation (eg, herbal supplements or traditional Chinese medicines) intended to treat the disease under study within 4 weeks prior to treatment. The concurrent use of any botanical preparation is not permitted while on study","ALL","18 Years",{"count":73,"type":22},30,[75],"PHASE2","By incorporating a platform trial protocol design, SELECTmeso will spearhead a next-generation precision medicine trial platform in relapsed mesothelioma for the UK enabling early evaluation of hypothesis-driven targeted therapies. The SELECTmeso Platform trial protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for patients with relapsed mesothelioma into the platform. Candidate Specific Trials (CSTs) will be added into the trial via treatment-specific CSTs of this platform trial protocol as appendices. Having one platform trial protocol ensures different candidates are evaluated in the same consistent manner and that opening up new trials for new candidates is more efficient.\n\nSELECTmeso1 is our first Candidate Specific Trial (CST) on the platform. SELECTmeso1 is investigating if a drug called BMS-986504 is effective in shrinking mesothelioma tumours as a targeted treatment for patients with tumours that have specific genetic biomarkers. Biomarkers are molecules that can indicate normal or abnormal processes taking place in the body or tumour, they can indicate how effective certain treatments will be. BMS-986504 has shown to be tolerated and promising signs of activity on patients with MTAP-deficient solid tumours, in a previous mesothelioma trial.",[78],"Mesothelioma",[80,68,81],"MTAP","Meso","2026-05-15",{"date":84,"type":39},"2026-05-22",{"date":86,"type":22},"2026-05-11",{"date":88,"type":22},"2027-08",{"name":45,"class":46},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":16,"sex":70,"minAge":71,"maxAge":19,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":47},"100504362","periscope-phase-c-bordetella-pertussis-human-challenge-study-with-delayed-antibiotic-therapy-for-6-weeks-100504362","NCT05847322","Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks","A Human Controlled Infection Study to Establish Safety of Infection With Bordetella Pertussis With Antibiotic Therapy Delayed for up to 6 Weeks","Inclusion Criteria:\n\n* Healthy adults aged 18 to 55 years inclusive on the day of screening\n* Fully conversant in the English language\n* Able to communicate easily by both mobile telephone, email and text messaging\n* Able and willing (in the investigator's opinion) to comply with all study requirements\n* Written informed consent to participate in the study\n* Willingness to take a curative antibiotic regimen if \u002F when required according to the study protocol\n* Willingness to abide by infection control guidelines during social contact for the duration of their participation in the study\n* Willingness to attend to the National Institute for Health Research (NIHR) Clinical Research Facility (CRF) Southampton immediately if they become symptomatic\n* Agreement to have no bedroom contacts other than their corresponding contact\u002Fchallenge volunteer between inoculation and 6 weeks after inoculation\n* Able to answer all questions on the pre-consent questionnaire correctly\n\nExclusion Criteria:\n\n* Individuals living in the same households as:\n\n  1. unimmunised or partially immunised children and infants aged \\\u003C 1 year\n  2. pregnant women \\>32 weeks who have not received pertussis vaccination at least a week prior to contact\n  3. immunosuppressed individuals\n  4. frail individuals\n  5. healthcare workers regularly working with vulnerable individuals as above\n* Individuals who have inviolable commitments within the study period (from day 0 to week 6 + 2 days) to be in close contact with:\n\n  1. unimmunised or partially immunised children and infants aged \\\u003C 1 year\n  2. pregnant women \\>32 weeks who have not received pertussis vaccination at least a week prior to contact\n  3. immunosuppressed individuals\n  4. frail individuals\n* Individuals who live in a boarding school or dormitory during the study.\n* B. pertussis detected on nasal wash taken before the initial challenge\n* Individuals with a confirmed or suspected infection at the time of inoculation with B. pertussis\n* Individuals who have participated in other interventional clinical trials in the last 12 weeks\n* Individuals who have a history of receiving B. pertussis vaccination in the last 5 years\n* Individuals who have previously participated in a B. pertussis human challenge study\n* Individuals who have had a proven B. pertussis infection in the last 5 years\n* Individuals who have a history of never being vaccinated against B. pertussis\n* Current smokers defined as having had a cigarette\u002Fcigar in the last week (including vaping)\n* Use of systemic antibiotics within 30 days of or during the challenge\n* Any confirmed or suspected immunosuppressive or immune-deficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (topical steroids are allowed)\n* Use of immunoglobulins or blood products within 3 months prior to enrolment\n* History of allergic disease or reactions likely to be exacerbated by any component of the inoculum\n* Contraindications to the use of azithromycin or macrolides\n* Pregnancy, lactation or intention to become pregnant during the study\n* Any clinically significant abnormal finding on biochemistry, haematology, toxicology or serological blood tests, urinalysis (see The following reference ranges are provided for the purpose of guidance only. Results that fall outside of these ranges may not be of clinical significance but should be considered on an individual basis.) or clinical examination - in the event of abnormal test results, confirmatory repeat tests will be requested\n* Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data, for example recent surgery to the nasopharynx\n\nExclusion criteria - Contact volunteers\n\n* Individuals living in the same households as:\n\n  1. unimmunised or partially immunised children and infants aged \\\u003C 1 year\n  2. pregnant women\n  3. immunosuppressed individuals\n  4. frail individuals\n  5. healthcare workers working with vulnerable individuals as above\n* Individuals who have inviolable commitments within the study period (from day 0 to week 6 + 2 days) to be in close contact with:\n\n  1. unimmunised or partially immunised children and infants aged \\\u003C 1 year\n  2. pregnant women \\>32 weeks who have not received pertussis vaccination at least a week prior to contact\n  3. immunosuppressed individuals\n  4. frail individuals\n* Individuals who have been involved in other clinical trials involving receipt of an investigational product over the last 12 weeks or if there is planned use of an investigational product during the study period\n* Individuals who have previously participated in a B. pertussis human challenge study\n* Individuals who have a history of never being vaccinated against B. pertussis\n* Any confirmed or suspected immunosuppressive or immune-deficient state, including HIV infection; malignancy, asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (topical steroids are allowed)\n* Contraindications to the use of azithromycin or macrolides\n* Any clinically significant abnormal finding on clinical examination\n* Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data\n* Pregnancy, lactation or intention to become pregnant during the study",{"count":98,"type":22},72,[25],"Primary objective- To assess the safety of nasal inoculation of healthy volunteers with B. pertussis with antibiotic therapy given to eradicate colonisation at 6 weeks after inoculation or at symptom onset, whichever occurs first\n\nSecondary objectives - To measure the rate of natural clearance of carriage of B. pertussis following nasal inoculation\n\n* To assess the kinetics of B. pertussis colonisation density following nasal inoculation\n* To describe the microevolution of B. pertussis and adaptation of the resident microbiome during B. pertussis carriage\n* To measure B. pertussis-specific antibody and cellular immunological responses in healthy volunteers during colonisation with B. pertussis - To identify biomarkers that correlate with natural clearance of B. pertussis carriage after induced B. pertussis colonisation\n* To detect transmission of B. pertussis to bedroom contacts of inoculated volunteers during prolonged asymptomatic colonisation",[102],"Healthy Volunteer Study","2026-05-14",{"date":105,"type":39},"2026-05-18",{"date":107,"type":39},"2022-12-06",{"date":109,"type":22},"2026-12-01",{"name":45,"class":46},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":70,"minAge":71,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":47},"100484128","phase-3-cellulitis-optimal-antibiotic-treatment-100484128","NCT05584007","Cellulitis Optimal Antibiotic Treatment","A Blinded, Non-inferiority Phase III Trial of 5 Versus 7 Days of Oral Flucloxacillin in Primary Care Patients With Lower Limb Cellulitis","COAT","Inclusion Criteria:\n\n* Must be aged 18 years or older\n* Currently showing symptoms of cellulitis (such as pain, tenderness, redness, other change in skin color, warmth to touch) in one leg for 10 days or less\n* Pain rated as 3\u002F10 or higher on a numerical rating scale (0-10) at baseline assessment\n* Be willing to be randomized to either trial arm (5-day or 7-day treatment)\n* Able to complete trial procedures in the English language.\n\nExclusion Criteria:\n\n* Have penicillin allergy\n* Have bilateral cellulitis\n* Have had antibiotics for cellulitis within the past month\n* Have post-operative cellulitis (within 30 days of operative procedures on the same leg)\n* Have cellulitis resulting from human\u002Fanimal bite injury\n* Have Cellulitis associated with chronic (\\>6 weeks) leg ulceration\n* Require immediate hospital admission or out-patient intravenous antibiotic therapy",{"count":120,"type":22},334,[122],"PHASE3","To determine whether a short course of oral flucloxacillin (5 days) is non-inferior to a standard course (7 days) in terms of pain over days 6-14 (indicative of persistence or recurrence associated with the symptoms of most importance to patients) in adults with cellulitis of the leg presenting in primary care.",[125],"Cellulitis of Leg",[127,128,129,130,131],"Primary care","Antibiotic treatment","Antibiotic resistance","Pain","Cost consequences",{"date":82,"type":39},{"date":134,"type":39},"2023-08-29",{"date":136,"type":22},"2027-07",{"name":45,"class":46},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":16,"sex":70,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100517468","promoting-increased-physical-activity-in-hospitalised-older-adults-100517468","NCT06017934","Promoting Increased Physical Activity in Hospitalised Older Adults","PIVOT Trial: Promoting Increased Physical Activity in Hospitalised Older Adults With Trained Volunteers: An Implementation Feasibility Study","PIVOT","Inclusion Criteria:\n\nPatients\n\n* Adults aged 65 years and above\n* Able to provide written informed consent\n\nVolunteers\n\n* Adults aged 18 years and above\n* Completed the generic clearance and training with the hospital voluntary services\n* Able to provide written informed consent\n* Able to communicate fluently enough in English. Fluent English is required to ensure the intervention content can be delivered clearly and thus safely to participants.\n\nExclusion Criteria:\n\nPatients\n\n* Anyone with a severe cognitive impairment (MoCA less than 10)\n* Patients isolated for infection control reasons\n* Patients receiving end of life care\n\nVolunteers\n\n* Volunteers that are unable to safely complete the exercises included in the intervention will be excluded from the study.","65 Years",{"count":148,"type":22},225,[25],"The PIVOT study will explore the feasibility of training volunteers to deliver exercise to hospitalised older adults to improve the health of older people and prevent deconditioning while in hospital. Loss of strength and mobility (i.e., deconditioning) is common in hospitalised older people and is associated with a decline in physical function, poorer quality of life and increased health and care costs. Physical inactivity is an important and modifiable risk factor. A previous study showed it is feasible to train volunteers to engage with older people in hospital and facilitate walking and bedside exercises. The intervention was well-received by older adults, staff members and volunteers. The aim of this study is to determine the feasibility of implementing volunteer-led physical activity in three hospitals of varying sizes in different regions.\n\nOlder adults aged 65 years and above admitted to an acute hospital will be invited to participate in the study. The study aims to recruit 180 participants; 90 from three intervention sites and 90 from a control site. Participants at the intervention sites will receive a twice daily volunteer-led physical activity intervention, and participants at the control site will receive usual care.\n\nParticipants who are able to mobilise independently will perform walking exercises and individuals with mobility impairments will perform bedside exercises. The volunteers will be trained and monitored by hospital therapists. The acceptability of the intervention will be explored through interviews with patients, volunteers, and staff. Intervention feasibility will also be examined through measuring retention of trainers, volunteers, and patients on the intervention, and adherence to the exercise.\n\nStudy findings will help to determine the feasibility of the volunteer-led physical activity intervention across different sized hospitals, voluntary service teams, and therapy services to explore the implementation and roll out of the intervention across NHS sites and the development of a toolkit to support knowledge transfer.",[152],"Hospital-associated Deconditioning",[154,155,156,157,158,159,160],"Physical activity","Hospital-associated deconditioning","Sedentary behaviour","Physical inactivity","Volunteer-led","Feasibility","Implementation","2026-05-12",{"date":163,"type":39},"2026-05-13",{"date":165,"type":39},"2024-06-06",{"date":167,"type":22},"2026-11",{"name":45,"class":46},2,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":70,"minAge":71,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":169},"100578732","a-novel-ureteric-stent-in-kidney-stone-patients-and-oncology-patients-compared-to-a-conventional-jj-stent-100578732","NCT06815120","A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent","Two Single Arm, Multicentre Unblinded First-in-human Trials Investigating a Novel Ureteric Stent to Determine the Reduction of Encrustation, Biofilm Deposition and Complications Compared to a Conventional JJ Stent","CASSETTE","Inclusion Criteria:\n\n1. Aged 18 years or over\n2. Ureteric stents clinically indicated either due to kidney stones or abdominal\u002Fpelvic cancers compressing ureters\n3. Previous experience with ureteric stents\n4. Awaiting insersion\u002Freplacement of stents\n5. Ability to give consent\n6. Ability to interact with study documentation\n7. Sufficient English to complete study documentations and questionnaires\n\nExclusion Criteria:\n\n1. Expected survival \\\u003C4months\n2. Unfit for stent insertion\n3. Unable to comply with study processes Pregnancy","99 Years",{"count":180,"type":22},50,[25],"Urological stents and catheters often lead to inflammation, causing pain and infection in the urinary tract. Moreover, 80% of stents are associated with pain, negatively impacting on QoL and mental health. Offering novel designs with significantly lower E\\&B leads to a reduction in UTIs and improves QoL. Reducing hospital admissions (from 3 to 1 per patient, annually) would free \\>100,000 bed-nights, allowing the elderly to regain independence. Our proposed research could have a significant impact towards fulfilling the 'healthy-ageing' Grand Challenge. Additionally, the novel stent reduces prevalence of infections and therefore, of antibiotic prescriptions contributing to the Global AMR challenge.",[184,185,186],"Catheter Blockage","Oncology","Kidney Stone","2026-05-06",{"date":86,"type":39},{"date":190,"type":39},"2025-08-06",{"date":192,"type":22},"2026-12-31",{"name":45,"class":46},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":70,"minAge":71,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":4},"100633791","developing-resource-interventions-for-healthcare-professionals-and-patients-to-improve-knowledge-about-fertility-in-primary-ciliary-dyskinesia-100633791","NCT07531277","Developing Resource Interventions for Healthcare Professionals and Patients to Improve Knowledge About Fertility in Primary Ciliary Dyskinesia","REproductive Health in PRimary Ciliary Dyskinesia: Developing User-informed Clinical and Educational Resources (REPRoDUCE)","REPRoDUCE","Inclusion Criteria:\n\n1. Aged 18 years or older\n2. 'Highly likely' or confirmed diagnosis of Primary Ciliary dyskinesia, or being a healthcare professional, or representative from a stakeholder group e.g. patient led charity\n3. Able to understand and willing to sign the informed participant consent prior to participation\n\nExclusion Criteria:\n\n1. Unwilling to participate in the study\n2. Not meeting inclusion criteria\n3. Unable to understand or unwilling to sign the informed participant consent prior to participation",{"count":73,"type":22},[25],"This project will involve working with people with PCD and medical professionals to develop resources that will help patients and the people providing their care to better understand fertility and pregnancy safety in people with this condition.",[206,207,208,209],"Primary Ciliary Dyskinesia (PCD)","Fertility","Pregnancy","Health Information Exchange","2026-04-08",{"date":212,"type":39},"2026-04-15",{"date":214,"type":22},"2026-04-01",{"date":216,"type":22},"2029-03-31",{"name":45,"class":46},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":70,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":47},"100555513","phase-3-study-to-evaluate-the-non-inferiority-of-low-dose-hipec-versus-high-dose-hipec-in-the-treatment-of-pmp-hipec-pmp-100555513","NCT06513065","Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)","A Single Blinded Randomised Controlled Study to Evaluate the Non-inferiority of HIPEC With Mitomycin C 10 mg\u002Fm2 for 60 Minutes Versus HIPEC With Mitomycin C 35mg\u002Fm2 for 90 Minutes in the Treatment of Pseudomyxoma Peritonei From Perforated Epithelial Mucinous Tumours of the Appendix","HIPEC-PMP","Inclusion Criteria:\n\n1. Clinical and\u002For radiological diagnosis of pseudomyxoma peritonei from a primary mucinous epithelial tumours of the appendix (low and high grade)\n2. The extent of intraperitoneal disease must be deemed to be amenable to complete cytoreduction (CC0-1, i.e. residual disease of \\\u003C 2.5mm in diameter).\n3. Patients aged 16 or more and capable of giving informed consent for the procedures and interventions of the current trial.\n4. ECOG performance status 0-1.\n\n   Exclusion Criteria:\n5. Patients who have previously undergone cytoreductive surgery and\u002For intraperitoneal chemotherapy.\n6. Clinical evidence or suspicion of metastases to sites different than peritoneum or intra-abdominal lymph nodes\n7. Hypersensitivity to the active substance (mitomycin) or its excipients (mannitol, hydrochloric acid, sodium hydroxide)\n8. Patients with conditions which may affect their ability to understand, retain and weigh up the information related to the requirements and consenting process of the study\n9. Women who are pregnant or breastfeeding.","16 Years",{"count":228,"type":22},176,[122],"The Investigators are researching how to improve the treatment currently available for patients diagnosed with Pseudomyxoma Peritonei (PMP). This is a rare cancer that usually starts in the appendix and spreads around the abdomen.\n\nPMP is usually treated using a type of surgery called Cytoreductive Surgery (CRS). During the surgery heated chemotherapy will also be used to treat any cancer cells that cannot be seen and may be left behind. This is called Hyperthermic Intraperitoneal Chemotherapy (HIPEC).\n\nThis treatment is commonly used in the UK and in Europe, however, the chemotherapy can be given at two different doses: a lower dose over 60 minutes or a higher-dose over 90 minutes.\n\nThe Investigators want to understand if there is a difference between these two doses. The higher dose has been associated with a slightly increased rate of complications but may be better at killing cancer cells and preventing recurrence of cancer. In Basingstoke the lower dose over 60 minutes is used and survival results are similar to centres who use the higher dose.\n\nPrevious studies have shown that both doses are effective at treating PMP, but no research has shown which is better for patients. The Investigators hope to show that the lower-dose over 60-minutes is as good as the higher-dose over 90-minutes.",[232],"Pseudomyxoma Peritonei",[234,235,236,237],"Psuedomyxoma Peritonei","Mitomycin C","Hyperthermic Intraperitoneal Chemotherapy","Appendix","2026-02-17",{"date":240,"type":39},"2026-02-19",{"date":242,"type":39},"2024-12-04",{"date":244,"type":22},"2029-04",{"name":45,"class":46},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":16,"sex":70,"minAge":254,"maxAge":178,"enrollmentInfo":255,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":258,"conditions":259,"keywords":265,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100576855","paediatric-breakthrough-pain-assessment-100576855","NCT06790719","Paediatric Breakthrough Pain Assessment","Development and Validation of a Paediatric Breakthrough Pain Assessment Tool","BEACON","Inclusion Criteria:\n\n* Children and young people aged 8-25 years who have experienced 1) background pain related to a life limiting or life threatening condition and 2) around-the-clock analgesia prescribed for the previous week, as confirmed by their healthcare team (Studies 1, 2, and 3).\n* Children and young people must be able to communicate and read in English at a level close to, or in line with their chronological age.\n* For study 1, non-verbal children and young people, or those with limited verbal ability, will be recruited if they are happy to participate using the Microsoft Teams chat function.\n* Parents and caregivers of children and young people aged 3-month-25-years who have experienced 1) background pain related to a life limiting or life threatening condition and 2) around-the-clock analgesia prescribed for the previous week, as confirmed by their healthcare team. (Studies 1, 2, and 3).\n* Caregivers can be caring for verbal, non-verbal, or pre-verbal children with or without cognitive or developmental difficulties of any level.\n* Parents and caregivers must have self-reported full or partial responsibility for assessing the child or young person's pain.\n* Healthcare professionals in primary, secondary and tertiary care who are involved in the care of children and young people with life limiting or life threatening conditions (Studies 2 and 3).\n\nExclusion Criteria:\n\n* • Children, young people, parents and caregivers with limited ability to communicate and read in English.\n\n  * Children and young people judged by caregivers or healthcare professionals to lack capacity to take part, who are too unwell, or might find it too distressing.\n  * Parents and caregivers judged by healthcare professionals to lack capacity to consent, or to be 'struggling' too much. However, if they wish to take part, they can send an email or text message to the study email account or mobile phone.","8 Years",{"count":256,"type":22},210,"OBSERVATIONAL","Many children and young people with life-limiting and life-threatening illnesses get sudden bursts of pain called breakthrough pain. At the moment, there aren't any good ways to measure this pain in children and young people. The investigators are developing two questionnaires to help: one for patients to fill out themselves and another for parents or healthcare professionals to complete for younger children and young people who cannot explain their pain for themselves.\n\nThe investigators plan to work with 210 people across hospitals and hospices in England and Wales. This includes children and young people with life-limiting and life-threatening illnesses, their caregivers, and healthcare professionals. The investigators have already made a first version of the questionnaires.\n\nThe project has three main Studies:\n\nIn Study 1, the investigators will talk to 5-10 young patients and 5-10 caregivers about their experiences with breakthrough pain. The investigators will use their feedback to improve the questionnaires.\n\nIn Study 2, the investigators will ask 5-10 patients, 5-10 caregivers, and 5-10 healthcare professionals to fill out the questionnaires while speaking their thoughts out loud. This will help the investigators find any parts that are confusing or difficult to understand.\n\nIn Study 3, the investigators will test how well the questionnaires works. 80 patients, 40 caregivers, and 40 healthcare professionals will complete the questionnaires three different times to make sure they measure breakthrough pain as accurately as possible.\n\nThese questionnaire will be useful for hospitals and hospices across England and Wales to help them better manage pain, including breakthrough pain, in patients aged 3 months to 25 years who have life-limiting and life-threatening illnesses.",[260,261,262,263,264],"Breakthrough Pain","Palliative Medicine","Oncology Pain","Pediatric ALL","Young People",[266,267,268,269,270],"Breakthrough pain","paediatrics","paediatric pain","palliative care","pain assessment","2025-01-17",{"date":273,"type":39},"2025-01-24",{"date":275,"type":22},"2025-01-20",{"date":277,"type":22},"2025-12",{"name":45,"class":46},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":70,"minAge":71,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":308},"100513439","phase-2-developing-ctdna-guided-adjuvant-therapy-for-gastrooesophageal-cancer-100513439","NCT05965479","Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","A Single Arm Phase II Trial of Trastuzumab Deruxtecan in Patients With Gastrooesophageal Adenocarcinoma Cancer Who Are ctDNA and HER2 Positive","DECIPHER","Inclusion Criteria:\n\n* Pathologically documented adenocarcinoma of the stomach (clinical stage before surgery of AJCC I-III), gastroesophageal junction, or lower oesophagus (to include Type I Siewert only), with HER2 overexpression (IHC 3+ or IHC 2+\u002FISH+) based on local tissue testing results.\n* ctDNA positive after surgery as per Signatera assay\n* Capable of giving signed informed consent prior to any mandatory study specific procedures, sampling, or analyses and which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n* Male and female participants must be at least 18 years of age at the time of signing the ICF.\n* Treated with neoadjuvant chemotherapy before surgery for at least six weeks.\n* Surgical resection with clear margins (R0).\n* Recovered from surgery in the opinion of the investigator.\n* No previous treatment with trastuzumab or other HER2 directed therapy.\n* No evidence of metastatic disease on post-surgical CT.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Has LVEF ≥ 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before treatment.\n* Has adequate organ and bone marrow function within 14 days before treatment allocation as below:\n* Platelet count ≥ 100x109\u002FL (Platelet transfusion is not allowed within 1 week prior to screening assessment, use of thrombopoietin receptor agonists is not allowed within 2 weeks prior to screening assessment)\n* Haemoglobin ≥ 80 g\u002FL. Participants requiring transfusions or growth factor support to maintain haemoglobin ≥ 80 g\u002FL are not eligible. (Red blood cell transfusions is not allowed within 1 week prior to screening assessment)\n* Absolute neutrophil count ≥ 1.5 x 109\u002FL (granulocyte-colony stimulating factor \\[G-CSF\\] administration is not allowed within 1 week prior to screening assessment\n* ALT\u002FAST ≤ 3 x ULN\n* Total bilirubin ≤ 1.5 x ULN or \\\u003C 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia)\n* Serum albumin ≥ 3.0 g\u002Fdl\n* Creatinine clearance ≥ 50 mL\u002Fmin as calculated using the Cockcroft-Gault equation\n* Adequate clotting function International Normalized Ratio (INR) or prothrombin time and either partial thromboplastin or activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN.\n* Reproduction:\n* Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilised male partner.\n* For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU\u002FmL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of IMP.\n* Women of childbearing potential are defined as those who are not surgically sterile (i.e., underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.\n\nI. Women aged \\\u003C50 years will be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site.\n\nII. Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\> 1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago.\n\n* Female participants of childbearing potential who are sexually active with a non-sterilised male partner must use at least one highly effective method of contraception from the time of screening, and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective.\n* Female participants must refrain from breastfeeding and must not donate (or retrieve their own for use) ova, from the time of screening, throughout the study treatment period, and for at least 7 months after the last dose of IMP.\n* Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is in line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasion abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.\n* Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to 4 months after the final dose of IMP.\n* It is strongly recommended for the female partners of a male participant to also use at least one highly effective method of contraception throughout this period. In addition, male participants should refrain from fathering a child or freezing or donating sperm from screening, throughout the study treatment period, and for at least 4 months after the last dose of IMP.\n* Investigators should advise male participants on the conservation of sperm prior to starting treatment because of the possibility of irreversible infertility\u002Ftesticular damage due to IMP administered in this study.\n* Female subjects must not donate, or retrieve for their own use, ova from the time of enrolment and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova prior to enrolment in this study, can be discussed with the patient if clinically appropriate to do so.\n\nExclusion Criteria:\n\n* Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AE's, or compromise the ability of the participant to give written informed consent.\n* Participants with a medical history of myocardial infarction within 6 months before treatment or symptomatic CHF (New York Heart Association Class II to IV), unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (\\\u003C6 months) cardiovascular event, including myocardial infarction, unstable angina pectoris, and stroke. Participants with troponin levels above ULN at screening (as defined by the manufacturer)m and without myocardial related symptoms, should have a cardiologic consultation before enrolment to rule out myocardial infarction.\n* Corrected QT interval (QTcF) prolongation to \\> 470 msec (females) or \\> 450 msec (males) based on average of the screening triplicate 12-lead ECG\n* History of (non-infectious) ILD\u002Fpneumonitis, current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n* Any of the following:\n\n  1. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., clinically significant pulmonary emboli within 3 months of treatment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, clinically significant pleural effusion etc.)\n  2. Any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis etc.), where there is documented, or a suspicion of, pulmonary involvement at the time of screening\n  3. Prior pneumonectomy (complete)\n* Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals\n* Multiple primary malignancies within the prior 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumours curatively treated.\n* A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt.\n* Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline. The following exemption will apply; stable chronic G2 toxicity which in the opinion of the investigator is not reasonably expected to be exacerbated by treatment with study drugs.\n* Known allergy or hypersensitivity to T-DXd or any of the study drug components\n* History of severe hypersensitivity reactions or other monoclonal antibodies\n* Pregnant or breastfeeding female participants, or participants who are planning to become pregnant\n* Involvement in the planning and\u002For conduct of the study\n* Has substance abuse or any other medical conditions, that may, in the opinion of the investigator, interfere with the subjects participation in the clinical study or evaluation of the clinical study results\n* Receipt of live, attenuated vaccine within 30 days prior to the first dose of trastuzumab deruxtecan. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IMP\n* Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Patients positive for hepatitis (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Judgement by the Investigator that the participant should not participate in the study, if the participant is unlikely to comply with study procedures, restrictions, and requirements.",{"count":288,"type":22},25,[75],"Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and surgery. 25 patients will be recruited from approximately 15 NHS secondary care sites.",[292],"Gastrooesophageal Cancer",[294,295,296,297,298,299],"Gastrooesophageal adenocarcinoma","Oesophageal cancer","Gastric cancer","HER2","ctDNA","Minimal residual disease","2024-11-07",{"date":302,"type":39},"2024-11-12",{"date":304,"type":39},"2024-04-10",{"date":306,"type":22},"2028-04-30",{"name":45,"class":46},14,{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":16,"sex":70,"minAge":146,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":47},"100506895","diagnosing-care-home-uti-study-100506895","NCT05880329","DIagnoSing Care hOme UTI Study","Feasibility Cohort Study on Predictors of Diagnosis and Prognosis of Urine Infection in Care Home Residents: DIagnoSing Care hOme UTI Study","DISCO UTI","Inclusion Criteria:\n\n* Willing and able to give informed consent for the study, or if lacking capacity, a consultee willing to complete a consultee declaration form.\n* Permanently living in a care home (nursing, residential or mixed).\n* Aged 65 or over.\n\nExclusion Criteria:\n\n* Current\u002Frecent suspected UTI (within last 4 weeks). However, may be reassessed for eligibility after 4 weeks.\n* Temporary\u002Frespite resident (unlikely to remain living in the care home for the 6 months of the study duration)\n* Terminal illness limiting life expectancy such that inclusion would be inappropriate (as judged by care home staff).\n* Known to have a medical condition or be on treatment that is likely to result in severe impairment of the immune system. For example, neutropenia, recent cancer chemotherapy or radiotherapy, or long-term use of oral steroids or other immunosuppressant medication.\n* Experiencing faecal incontinence to the extent that it is impossible to obtain an uncontaminated urine sample (as determined by care home staff).\n* Indwelling urinary catheter or regular use of intermittent catheterisation.\n* Structural urological abnormalities. For example, renal polycystic disease, horseshoe kidney, hydronephrosis, renal hypoplasia\n* Current renal tract malignancy. However, residents with prostate cancer will be eligible if they do not require catheterisation and are not considered terminally ill.",{"count":318,"type":22},100,"The number of care home residents is increasing and urinary tract infections (UTIs) are common amongst this group. Accurate diagnosis of UTI is important because not treating an infection may lead to serious consequences including death. However, giving antibiotic treatment when there isn't an infection causes side effects and antibiotic resistance, making future infections harder to treat.\n\nUnfortunately, there are several challenges that mean that it is difficult to diagnose UTI accurately in care home residents. Firstly, UTIs don't always cause clear symptoms for people who live in care homes. They sometimes just cause symptoms like confusion which can have lots of different possible causes. Secondly, it may be hard for people living with dementia to say how they are feeling or to easily provide a urine sample. Thirdly, many people who live in care homes have bacteria present in their urine even when they are well, but this not harmful and does not need treatment. Finally, urine tests that are currently available do not give accurate or quick results.\n\nWe have thought about some new ways that might help show us if someone in a care home really has a UTI but we don't know yet whether these will work. Our ideas include 1) Working out which symptoms or signs mean a UTI is more likely 2) Detecting new markers of infection in urine samples and 3) Trying out new bedside tests that give rapid results.\n\nFor this study we plan to recruit 100 care home residents who will be followed up over 6 months. All 100 participants will provide information and a urine sample at the beginning of the study. 25 of these participants will also provide repeated weekly samples for 4 weeks to look at any changes in the urine over time. Additional information and urine samples will be collected if a participant develops a possible UTI during the study and any treatments will be recorded.\n\nOur findings will be used to develop a funding application for a larger study aiming to improve the diagnosis of UTI in care home residents.",[321],"Urinary Tract Infections","2024-07-30",{"date":324,"type":39},"2024-07-31",{"date":326,"type":39},"2023-09-01",{"date":328,"type":22},"2025-03-31",{"name":45,"class":46},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":70,"minAge":71,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":345,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100555517","living-better-with-asthma-study-a-multimodal-intervention-to-address-multimorbidity-in-difficult-asthma-100555517","NCT06513117","LIving BEtteR With asThma studY:: A Multimodal Intervention to Address Multimorbidity in Difficult Asthma","LIving BEtteR With asThma studY: A Multimodal Intervention to Address Multimorbidity in Difficult Asthma","LIBERTY","Inclusion Criteria:\n\nAged 18 to 80 years Able and willing to give informed consent Diagnosis of asthma determined by\n\n1. clinical diagnosis of difficult asthma as defined by BTS steps 4-5 and\n2. enrolled in WATCH or meet WATCH inclusion criteria.\n3. Demonstration of suboptimal symptom control through an ACQ ≥ 1.5 at enrolment\n4. Normal lung function or mild\u002Fmoderate airflow obstruction at baseline (FEV1\\>50% predicted)\n5. Not achieving WHO recommendations for physical activity for people living with chronic health conditions(62) (150-300 minutes of moderate-intensity aerobic physical activity; or at least 75-150 minutes of vigorous-intensity aerobic physical activity; or an equivalent combination of moderate- and vigorous-intensity activity throughout the week) 6)12 lead ECG without clinically significant abnormality -\n\nExclusion Criteria:\n\n1. Intercurrent exacerbation or exacerbation within 4 weeks prior to enrolment in study requiring treatment with oral corticosteroids and\u002For antibiotics. Note participants can be rescreened 4 weeks post exacerbation if they had not commenced the study\n2. Initiation of biologic treatment within 6 months prior to recruitment or during study participation\n3. Investigator determined significant change in regular asthma medication in the 12 weeks preceding or during trial period\n4. Other medical or psychiatric conditions (including cognitive decline) limiting ability to exercise or that may in the opinion of the study clinician carry inherent risk for exercise\n5. Contraindication to ISWT\n6. Positive pregnancy test\n7. Beta blocker treatment (due to impact on exercise prescription using HR) -","80 Years",{"count":73,"type":22},[25],"Multimorbidity is a significant issue for many patients with difficult asthma. With patients, we have co-designed a multimodal intervention comprising prescribed exercise, dietary support, breathing pattern retraining and behaviour change to target multimorbidity in difficult asthma",[343,344],"Asthma","Multi Morbidity",[346,347,348,349],"exercise","behaviour change","multimorbidity","asthma","2024-07-24",{"date":352,"type":39},"2024-07-26",{"date":354,"type":22},"2024-10",{"date":356,"type":22},"2028-04",{"name":45,"class":46},""]